Expertise in
2
conditions

Dr. David Rosmarin

Psychiatry
McLean Hospital
115 Mill St, 
Belmont, MA 
Expertise in
2
conditions
McLean Hospital
115 Mill St, 
Belmont, MA 

Overview

David Rosmarin is a Psychiatrist practicing medicine in Belmont, Massachusetts.

Dr. Rosmarin is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Plaque Psoriasis, Discoid Lupus Erythematosus (DLE), Post-Traumatic Stress Disorder (PTSD), and Systemic Sclerosis (SSc).

He is actively involved in clinical research, co-authoring 184 peer reviewed articles and participating in 14 clinical trials.

Specialties

Psychiatry

Licenses

Psychiatry & Neurology in MA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO

Locations

McLean Hospital
115 Mill St, Belmont, MA 02478

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: April 07, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI)
Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI)
Enrollment Status: Completed
Publish Date: December 09, 2025
Intervention Type: Biological, Procedure
Study Drug: AMG 714
Study Phase: Phase 2
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Phase 2 Double Blind Randomized Placebo Controlled Trial of Topical Crisaborole in Patients with Mild-to-Moderate Alopecia Areata
Phase 2 Double Blind Randomized Placebo Controlled Trial of Topical Crisaborole in Patients with Mild-to-Moderate Alopecia Areata
Enrollment Status: Withdrawn
Publish Date: October 28, 2024
Intervention Type: Drug
Study Drug: Crisaborole
Study Phase: Phase 2
Apremilast 30 mg BID Combined With Dupilumab for the Treatment of Recalcitrant Moderate-to-Severe Atopic Dermatitis
Apremilast 30 mg BID Combined With Dupilumab for the Treatment of Recalcitrant Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: April 19, 2024
Intervention Type: Drug
Study Drug: Apremilast
Study Phase: Phase 2
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
View 9 Less Clinical Trials

184 Total Publications

Definition of Severity and Relapse for Vitiligo: An International Consensus Statement.
Definition of Severity and Relapse for Vitiligo: An International Consensus Statement.
Journal: JAMA dermatology
Published: March 25, 2026
Similar Doctors
Expertise in
16
conditions
Dr. Steven Arnold
Psychiatry
Expertise in
16
conditions
Dr. Steven Arnold
Psychiatry

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (6.6 miles away)
617-726-1728
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Steven Arnold is a Psychiatrist practicing medicine in Boston, Massachusetts. Dr. Arnold is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Normal Pressure Hydrocephalus, and Hydrocephalus.

Expertise in
4
conditions
Dr. Darin Dougherty
Psychiatry
Expertise in
4
conditions
Dr. Darin Dougherty
Psychiatry

McLean Hospital

115 Mill St, 
Belmont, MA 
 (0.2 miles away)
617-855-2775
Languages Spoken:
English
See accepted insurances

Darin Dougherty is a Psychiatrist practicing medicine in Belmont, Massachusetts. Dr. Dougherty is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Obsessive-Compulsive Disorder (OCD), Bipolar Disorder (BPD), Tourette Syndrome, Major Depression, and Deep Brain Stimulation.

Expertise in
6
conditions
Dr. Simon Ducharme
Psychiatry
Expertise in
6
conditions
Dr. Simon Ducharme
Psychiatry

Belmont Office

115 Mill St 238, 
Belmont, MA 
 (0.5 miles away)
617-855-2000
Languages Spoken:
English

Simon Ducharme is a Psychiatrist practicing medicine in Belmont, Massachusetts. Dr. Ducharme is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Frontotemporal Dementia, Dementia, Developmental Dysphasia Familial, and Alzheimer's Disease.

Frequently Asked Questions about Dr. David Rosmarin

How do I make an appointment with Dr. David Rosmarin?

You can book an appointment with Dr. David Rosmarin by calling their office at 617-699-8113. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David Rosmarin a top-rated expert for Plaque Psoriasis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David Rosmarin is classified as an Distinguished expert for Plaque Psoriasis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David Rosmarin specialize in?

While Dr. David Rosmarin is a Psychiatry, they have specific expertise in Plaque Psoriasis, Discoid Lupus Erythematosus (DLE), and Post-Traumatic Stress Disorder (PTSD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Psychiatry.

Does Dr. David Rosmarin participate in research or clinical trials?

Yes. Dr. David Rosmarin has published 184 articles and abstracts on conditions like Plaque Psoriasis. You can view a list of Dr. David Rosmarin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David Rosmarin accept my insurance?

Dr. David Rosmarin accepts most major insurance plans, including Blue Cross Blue Shield and Blue Shield of California. We recommend calling the office directly at 617-699-8113 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rosmarin's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile